CARLSBAD, Calif., Dec. 9 /PRNewswire/ -- Regulus Therapeutics Inc. will host an educational Webinar featuring a discussion with leading microRNA scientists: Tom Tuschl, Ph.D. Professor at Rockefeller University and Markus Stoffel, M.D., Ph.D. Professor at the Swiss Federal Institute of Technology. Dr. Tuschl will discuss the discovery of microRNA and its role as a master regulator of the genome, and Dr. Stoffel will discuss the elucidation of microRNA function in normal and disease states, and therapeutic strategies based on microRNA modulation.

What:      MicroRNA: The Year in Review

When:      3 p.m. EST on Monday, December 14

Where:     http://www.videonewswire.com/event.asp?id=64631

How:       Live over the Internet -- Simply log on at the address above.

      Contact:

                      Regulus Therapeutics
                      Garry E. Menzel, Ph.D.
                      (760)268-6811

                      Media
                      Heidi Chokeir, Ph.D.
                      Russo Partners, LLC
                      (619)528-2217
                      heidi.chokeir@russopartnersllc.com

About Regulus Therapeutics Inc.

Regulus Therapeutics is a biopharmaceutical company leading the discovery of innovative new medicines based on microRNAs. Regulus is targeting microRNAs as a new class of therapeutics by working with a broad network of academic collaborators and leveraging oligonucleotide drug discovery and development expertise from Alnylam Pharmaceuticals and Isis Pharmaceuticals (Alnylam and Isis jointly formed Regulus in 2007). Regulus is advancing microRNA therapeutics towards the clinic in several areas including hepatitis C infection, cardiovascular disease and fibrosis, oncology, and immunology and inflammation. Regulus intellectual property estate contains both the fundamental and core patents in the field as well as over 600 patents and more than 300 pending patent applications pertaining primarily to chemical modifications of oligonucleotides targeting microRNAs for therapeutic applications. In 2008, Regulus entered into a major alliance with GlaxoSmithKline to discover and develop microRNA therapeutics for immuno-inflammatory diseases. For more information, visit www.regulusrx.com.

Minimum Requirements to listen to broadcast:

The Windows Media Player software, downloadable free from http://www.microsoft.com and at least a 56Kbps connection to the Internet.

If you experience problems listening to the webcast, send an E-mail to: webcast@multivu.com.

SOURCE Regulus Therapeutics Inc.

Back to top

RELATED LINKS
http://www.regulusrx.com